This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Pluristem’s Off-The-Shelf Placenta-Derived Cell Therapies - The Focus Of Presentations At Upcoming Investor And Medical Conferences

Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced that its off-the-shelf placenta-derived cell therapies will be the focus of presentations at upcoming investor and medical conferences.

Chaya Mazouz, the company’s vice president of clinical and regulatory affairs, will present information about the regulatory study design considerations for PLX-PAD, the company’s lead cell therapy candidate for the treatment of critical limb ischemia (CLI), at 11 a.m. EDT on May 24 at the International Society for Cellular Therapy’s (ISCT) 16 th Annual Meeting in Philadelphia. She will also participate in a case study panel discussion: "Global Regulatory Perspectives Workshop", on May 23 at 3:15 p.m. EDT. Also at the meeting, Frida Grynspan, Pluristem’s vice president of research and development, will present an overview of the immunological profile of CLI patients following the intramuscular administration of PLX-PAD. Her presentation will take place at 10:45 a.m. EDT on May 25.

“We recently reported interim top-line results from our Phase I clinical trials demonstrating that PLX-PAD is safe, well tolerated and had improved the quality of life of CLI patients in the studies,” said Zami Aberman, Pluristem’s chairman and CEO. “With PLX-PAD, we have the unique opportunity to utilize a single source of cells, the placenta, to treat an unlimited number of CLI patients. Our presentations at the ISCT Annual Meeting and other conferences will highlight the potential of PLX-PAD as well as our core technology that enables the cost-effective development of cell therapies derived from the human placenta.”

At 1:15 p.m. EDT on June 1, Mr. Aberman will participate in a plenary session about the allogeneic approaches of cell therapy at the Stem Cell Investor & Executive Networking Conference Event (SCIENCE) in New York. Hosted by National Securities Corporation and MD Becker Partners, SCIENCE is designed to unite investors with industry executives to exchange information and highlight opportunities in the stem cell universe. The event will bring together researchers, clinicians, business leaders, key investors and other stakeholders in the cell therapy space.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs